NO20042209L - Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner - Google Patents

Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner

Info

Publication number
NO20042209L
NO20042209L NO20042209A NO20042209A NO20042209L NO 20042209 L NO20042209 L NO 20042209L NO 20042209 A NO20042209 A NO 20042209A NO 20042209 A NO20042209 A NO 20042209A NO 20042209 L NO20042209 L NO 20042209L
Authority
NO
Norway
Prior art keywords
translational modifications
post
mammalian cells
predetermined post
present
Prior art date
Application number
NO20042209A
Other languages
English (en)
Norwegian (no)
Inventor
Abraham Bout
Johan Christiaan Kapteyn
Petrus Christianus Joh Passier
Ronald Hendrik Peter Brus
Dirk Jan Elbertus Opstelten
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NL2001/000792 external-priority patent/WO2003050286A1/en
Priority claimed from PCT/NL2002/000257 external-priority patent/WO2003089468A1/en
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of NO20042209L publication Critical patent/NO20042209L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
NO20042209A 2001-10-29 2004-05-28 Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner NO20042209L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/NL2001/000792 WO2003050286A1 (en) 2001-10-29 2001-10-29 Methods and means for producing proteins with predetermined post-translational modifications
PCT/NL2002/000257 WO2003089468A1 (en) 2002-04-19 2002-04-19 Methods and means for producing proteins with predetermined post-translational modifications
PCT/NL2002/000686 WO2003038100A1 (en) 2001-10-29 2002-10-29 Methods and means for producing proteins with predetermined post-translational modifications

Publications (1)

Publication Number Publication Date
NO20042209L true NO20042209L (no) 2004-07-28

Family

ID=26642018

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042209A NO20042209L (no) 2001-10-29 2004-05-28 Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner

Country Status (14)

Country Link
US (3) US7304031B2 (pt)
EP (2) EP2292770B1 (pt)
JP (1) JP4583029B2 (pt)
CN (1) CN100347306C (pt)
AT (1) ATE542904T1 (pt)
AU (1) AU2002335585B2 (pt)
BR (1) BR0213402A (pt)
CA (2) CA2756610C (pt)
DK (1) DK1440157T3 (pt)
EA (2) EA012340B1 (pt)
ES (1) ES2381104T3 (pt)
IL (3) IL161674A (pt)
NO (1) NO20042209L (pt)
WO (1) WO2003038100A1 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
CN100347306C (zh) * 2001-10-29 2007-11-07 克鲁塞尔荷兰公司 生产具有预定的翻译后修饰的蛋白质的方法和手段
JP4480398B2 (ja) 2001-12-07 2010-06-16 クルセル ホランド ベー ヴェー ウイルス、ウイルス分離株及びワクチンの製造方法
US8524477B2 (en) * 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
WO2005090390A1 (en) * 2004-03-17 2005-09-29 Crucell Holland B.V. Novel assay for the separation and quantification of hemagglutinin antigens
JP2008527980A (ja) * 2005-01-25 2008-07-31 アポロ ライフ サイエンシズ リミテッド 分子およびそのキメラ分子
JP4200509B2 (ja) * 2005-06-01 2008-12-24 株式会社新潟Ｔｌｏ Ｅｐｏ誘導体含有血液関連疾患治療剤
AR053416A1 (es) * 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
JP5284789B2 (ja) * 2005-11-15 2013-09-11 グライコフィ， インコーポレイテッド Ｏ−グリコシル化を減少している糖タンパク質の生成
US7642078B2 (en) 2005-12-28 2010-01-05 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
WO2007092252A2 (en) * 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
WO2007098548A1 (en) * 2006-03-01 2007-09-07 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
AU2007255717B2 (en) 2006-06-07 2013-07-11 Chugai Seiyaku Kabushiki Kaisha Treatment of ischemic disease using erythropoietin
CA2661054A1 (en) 2006-08-22 2008-02-28 Chugai Seiyaku Kabushiki Kaisha Prophylactic and/or therapeutic agents for peripheral neuropathy
AR065613A1 (es) 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
ES2626080T3 (es) 2007-04-16 2017-07-21 Momenta Pharmaceuticals, Inc. Caracterización de N-glicanos utilizando exoglicosidasas
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
US8138092B2 (en) 2009-01-09 2012-03-20 Lam Research Corporation Spacer formation for array double patterning
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
WO2012131306A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
WO2013067322A1 (en) * 2011-11-03 2013-05-10 Stc Biologics, Inc. Method for determination of pharmacological properties of recombinant proteins
US9522945B2 (en) 2012-04-19 2016-12-20 Opko Biologics Ltd. Long-acting oxyntomodulin variants and methods of producing same
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
SG10202010383YA (en) 2012-11-20 2020-11-27 Opko Biologics Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
RU2711935C2 (ru) 2013-03-11 2020-01-23 Джензим Корпорейшн Сайт-специфическая конъюгация антитело-лекарственное средство посредством гликоинженерии
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2016004242A1 (en) * 2014-07-01 2016-01-07 Stc Biologics, Inc. A method for development of recombinant proteins with fingerprint like similarity to the reference product
EA201791275A1 (ru) 2014-12-10 2017-12-29 Опко Байолоджикс Лтд. Способы получения ctp-модифицированных полипептидов длительного действия
IL301728A (en) 2015-06-19 2023-05-01 Opko Biologics Ltd Long-term coagulation factors and methods for their preparation
HUE064463T2 (hu) 2016-07-11 2024-03-28 Opko Biologics Ltd Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások
CN109415426B (zh) * 2016-07-12 2022-03-11 赫克萨尔股份公司 具有降低的唾液酸残基的乙酰化率的糖蛋白
WO2018182529A1 (en) * 2017-03-29 2018-10-04 Agency For Science, Technology And Research Anti oligosaccharide antibody
MX2020003742A (es) * 2017-10-11 2020-10-28 Elanco Us Inc Variantes del factor estimulador de colonias de granulocitos de porcino y sus usos.
CN111514279B (zh) * 2020-06-16 2023-07-18 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 神经营养因子3在制备治疗男性性腺功能减退症的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU646822B2 (en) 1989-10-13 1994-03-10 Kirin-Amgen Inc. Erythropoietin isoforms
US5789247A (en) * 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
WO1998044141A2 (en) * 1997-03-27 1998-10-08 The University Of British Columbia Insect expression vectors
CA2221819A1 (en) 1997-03-27 1998-09-27 Thomas A. Gigliatti Insect expression vectors
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
CA2383940A1 (en) 1999-04-13 2000-10-19 The Kenneth S. Warren Laboratories, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
CN100457914C (zh) * 1999-04-15 2009-02-04 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FI109811B (fi) * 2000-09-26 2002-10-15 Medicel Oy Menetelmä GDP-L-fukoosin valmistamiseksi ja menetelmässä käytettäviä välineitä
DE10056136A1 (de) 2000-11-07 2002-05-16 Nemod New Modalities Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
EP2042196B1 (en) * 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
CN100347306C (zh) * 2001-10-29 2007-11-07 克鲁塞尔荷兰公司 生产具有预定的翻译后修饰的蛋白质的方法和手段
EP2314629B2 (en) * 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
WO2005090390A1 (en) * 2004-03-17 2005-09-29 Crucell Holland B.V. Novel assay for the separation and quantification of hemagglutinin antigens
US7183371B2 (en) * 2004-11-01 2007-02-27 General Electric Company Method for making polycarbonate
US20080139608A1 (en) * 2006-12-06 2008-06-12 Universiteit Leiden 2,6,8, Trisubstituted 1-deazapurines and their different uses

Also Published As

Publication number Publication date
EP2292770A3 (en) 2012-12-19
IL201674A (en) 2013-10-31
US7785833B2 (en) 2010-08-31
EP2292770B1 (en) 2014-11-26
US7696157B2 (en) 2010-04-13
US20050164917A1 (en) 2005-07-28
CA2756610C (en) 2015-08-25
EP1440157B1 (en) 2012-01-25
EA008220B1 (ru) 2007-04-27
ES2381104T3 (es) 2012-05-23
BR0213402A (pt) 2004-10-13
EA200400605A1 (ru) 2004-08-26
EP2292770A2 (en) 2011-03-09
CN100347306C (zh) 2007-11-07
CA2465007A1 (en) 2003-05-08
US7304031B2 (en) 2007-12-04
CN1578838A (zh) 2005-02-09
EA012340B1 (ru) 2009-10-30
CA2756610A1 (en) 2003-05-08
DK1440157T3 (da) 2012-05-07
JP2005507426A (ja) 2005-03-17
US20080032922A1 (en) 2008-02-07
EA200602163A1 (ru) 2007-04-27
US20070117742A1 (en) 2007-05-24
IL201673A (en) 2013-10-31
AU2002335585B2 (en) 2007-08-16
IL161674A (en) 2014-06-30
CA2465007C (en) 2012-01-17
JP4583029B2 (ja) 2010-11-17
WO2003038100A1 (en) 2003-05-08
EP1440157A1 (en) 2004-07-28
ATE542904T1 (de) 2012-02-15

Similar Documents

Publication Publication Date Title
DK1440157T3 (da) Methods and means for producing proteins with predetermined post-translational modifications
DE59608743D1 (de) Verfahren zur herstellung von rekombinanten proteinen in e. coli mittels hochzelldichte-fermentation
DE68921364D1 (de) Verfahren zur Herstellung von Proteinen mittels rekombinanter DNA.
DE69434578D1 (de) Expressionsvektoren die für bispezifische Proteine kodieren, und Verfahren zur Herstellung von biologisch-aktiven bispezifischen Fusionsproteine in Zellen von Säugertieren
DE69829976D1 (de) Verfahren zur trocknung von kompetenten zellen
DE69920747D1 (de) Methode zur herstellung von rekombinanten zellen
DE3486179D1 (de) Verfahren zur herstellung vielkettige polypeptide oder proteine.
DE69938867D1 (de) Verfahren und verwendung von anordungen von proteinfixierungsmitteln
ATE553125T1 (de) Herstellung eines multimeren proteins durch zellfusionsverfahren
NO911688D0 (no) Neurotrophin-3, en ny neurotrofisk faktor relatert til neurovekstfaktor og hjerne-avledet neurotrofisk faktor.
ATE500331T1 (de) Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
KR910004803A (ko) 간의 실질 세포 성장 인자, 이를 코딩하는 유전자, 이 인자를 생산하는 방법, 및 이 인자를 생산하는 형질전환체
ATE420061T1 (de) 13c,15n,2h markierte proteine zur nmr strukturbestimmung und deren herstellung
DE69632887D1 (de) Verfahren zur zweckmässige Herstellung von Transglutaminase durch DNA-Rekombination
ATE397061T1 (de) Verfahren zur herstellung von proteinen
DK0963377T3 (da) Interleukin-19
ATE433486T1 (de) Durchmusterung von bibliotheken exprimierter dna in filamentösen pilzen mit hoher durchsatzrate
ATE328102T1 (de) Verfahren zur herstellung von proteine
ATE220714T1 (de) Verfahren zur herstellung von proteinen
ATE375089T1 (de) Fraktioniertes sojabohnenprotein und herstellungsverfahren dafür
ATE435277T1 (de) 18477, eine menschliche proteinkinase und deren verwendung
DE69425809D1 (de) Methoden zur Herstellung von Protein C
ATE302214T1 (de) Enamel-matrix bezogene polypeptide
DE50011240D1 (de) Verfahren zur Modifizierung von Polymeroberflächen
DE69530261D1 (de) Durch Zelldichte stimulierte Protein-Tyrosin-Phosphatasen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application